Utama › Kanser Kolorektal › Kansas

Kajian klinikal Kanser Kolorektal di Kansas

19 kajian untuk Kanser Kolorektal sedang mencari peserta di lokasi di Kansas.

Bandar di Kansas

Teks kajian rasmi (Bahasa Inggeris)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Central Care Cancer Center - Garden City, Garden City
Central Care Cancer Center - Great Bend, Great Bend
Veteran Administration Eastern Kansas Healthcare, Leavenworth
dan 4 lagi

Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan

Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069

Family Communications After Genetic Testing

Central Care Cancer Center - Garden City, Garden City
Central Care Cancer Center - Great Bend, Great Bend
Mercy Hospital Pittsburg, Pittsburg
dan 1 lagi

Mengambil pesertaSukarelawan sihat dialu-alukan

Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07143487

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

University of Kansas Clinical Research Center, Fairway
University of Kansas Cancer Center, Kansas City
University of Kansas Hospital-Westwood Cancer Center, Westwood

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT05803382

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Research Site, Westwood

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06218914

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Cancer Center of Kansas, Wichita

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06750094

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Cancer Center of Kansas, Wichita

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06662786

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

University of Kansas, Fairway

Mengambil pesertaFasa 1

Umur 12 hingga 120 · Semua jantina · Dikemas kini 23 Sep 2026 · NCT04222413

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

The University of Kansas Clinical Research Center, Westwood

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06445062

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

University of Kansas Clinical Research Center, Fairway
University of Kansas Cancer Center, Kansas City
University of Kansas Hospital-Indian Creek Campus, Overland Park
dan 1 lagi

Mengambil pesertaFasa 1

Umur 18 ke atas · Semua jantina · Dikemas kini 9 Sep 2026 · NCT06696768

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

Clinical Study Site, Westwood

Mengambil pesertaFasa 3

Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT07228832

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

The University of Kansas Cancer Center, Kansas City

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 11 Ogo 2026 · NCT05592626

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

University of Kansas Clinical Research Center, Fairway
University of Kansas Cancer Center, Kansas City
University of Kansas Cancer Center-Overland Park, Overland Park
dan 2 lagi

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 31 Jul 2026 · NCT05691491

Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

Cancer Centers of Kansas, Wichita

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 15 Jul 2026 · NCT06937177

Lead-212 PSV359 Therapy for Patients With Solid Tumors

University of Kansas, Kansas City

Mengambil pesertaFasa 1/2

Umur 18 hingga 90 · Semua jantina · Dikemas kini 6 Jul 2026 · NCT06710756

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

The University of Kansas Clinical Research Center, Fairway

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 1 Jun 2026 · NCT06607458

Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

Central Care Cancer Center - Garden City, Garden City
Central Care Cancer Center - Great Bend, Great Bend
Mercy Hospital Pittsburg, Pittsburg

Mengambil pesertaFasa 3Sukarelawan sihat dialu-alukan

Umur 18 ke atas · Semua jantina · Dikemas kini 31 Mac 2026 · NCT07018869

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

The University of Kansas Cancer Center, Fairway

Mengambil pesertaFasa 1/2

Umur 18 ke atas · Semua jantina · Dikemas kini 18 Mac 2026 · NCT06244771

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

HaysMed, Hays
Lawrence Memorial Hospital, Lawrence
The University of Kansas Cancer Center - Olathe, Olathe
dan 6 lagi

Mengambil pesertaKajian pemerhatian

Umur 18 ke atas · Semua jantina · Dikemas kini 17 Mac 2026 · NCT06418204

A Study of IBI363 in Subjects with Advanced Solid Malignancies

University of Kansas Medical Center (KUMC), Fairway

Mengambil pesertaFasa 2

Umur 18 ke atas · Semua jantina · Dikemas kini 19 Dis 2024 · NCT06281678

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.